SCHEMBL289145

SCHEMBL289145

O=C(c1ccccc1)c1coc2ccc(O)cc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 5/20 0.81
KMT2A Q03164 5/20 0.74
NPC1 O15118 4/20 0.74
RAB9A P51151 3/20 0.74
MAPT P10636 2/20 0.74
CASP3 P42574 2/20 0.74
SENP7 Q9BQF6 2/20 0.74
SENP6 Q9GZR1 2/20 0.74
LMNA P02545 2/20 0.74
SENP8 Q96LD8 1/20 0.74
NFKB1 P19838 1/20 0.74
HTT P42858 1/20 0.74
NFKB2 Q00653 1/20 0.74
RELA Q04206 1/20 0.74
SMN1; SMN2 Q16637 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.66
HPGD P15428 2/20 0.62
MEN1 O00255 3/20 0.61
ALDH1A1 P00352 2/20 0.56
TSHR P16473 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27861098 0.87 SIRT1 (0.84) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL2915316 0.85 NPC1 (1.00) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL3377499 0.82 SIRT1 (0.66) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL6345667 0.82 KMT2A (0.61) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL29630236 0.82 SIRT1 (0.66) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL289081 0.81 NPC1 (1.00) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL9594944 0.81 NPC1 (0.60) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL16541098 0.80 RAB9A (1.00) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL31335179 0.79 SIRT1 (0.63) SIRT1KMT2ANPC1RAB9AMAPT
SCHEMBL20251011 0.77 KMT2A (0.61) SIRT1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2959898-A1 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2015-12-30 EP disclosed
EP-2959898-A1 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2015-12-30 EP disclosed
EP-2427057-B1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN KETTERING INST CANCER (US) 2015-08-12 EP disclosed
EP-2427057-B1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN KETTERING INST CANCER (US) 2015-08-12 EP disclosed
CN-102603825-B 5-thioxylopyranose derivatives FOURNIER LAB SA 2014-03-12 CN disclosed
US-8614237-B2 Benzofuran-4,5-diones as selective peptide deformylase inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2013-12-24 US disclosed
CN-101490073-B Derivatives of 5-thioxylopyranose FOURNIER LAB S A 2012-12-05 CN disclosed
CN-102603825-A New 5-thioxylopyranose derivatives FOURNIER LAB SA 2012-07-25 CN disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed
EP-2427057-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2012-03-14 EP disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed
WO-2010129049-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-11-11 WO disclosed
US-7652032-B2 5-Thioxylopyranose compounds LABORATOIRES FOURNIER S.A. (FR) 2010-01-26 US disclosed
EP-2041153-B1 NEW 5-THIOXYLOPYRANOSE DERIVATIVES FOURNIER LAB SA (FR) 2009-10-21 EP disclosed
CN-101490073-A Novel derivatives of 5-thioxylopyranose FOURNIER LAB S A (FR) 2009-07-22 CN disclosed
US-20090118325-A1 5-Thioxylopyranose Compounds LABORATOIRES FOURNIER S.A. (FR) 2009-05-07 US disclosed
EP-2041153-A1 NEW 5-THIOXYLOPYRANOSE DERIVATIVES Laboratoires Fournier S.A. (FR) 2009-04-01 EP disclosed
WO-2008007027-A1 NEW 5-THIOXYLOPYRANOSE DERIVATIVES LABORATOIRES FOURNIER S.A. (FR) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118325-A1 5-Thioxylopyranose Compounds STS, F2, CBR1 SIRT1 1480/4885KMT2A 4035/4885NPC1 3742/4885
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS PDF, EIF5B, EIF4E SIRT1 1438/4885KMT2A 3066/4885NPC1 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.